Global Systemic Lupus Erythematosus (SLE) Market (by Product Type, Route of Administration, End User, & Region): Insights & Forecast with Potential Impact of COVID-19 (2022-2026)

Description

Market Insight:

Systemic Lupus Erythematosus (SLE) is a multi-systemic, incurable autoimmune disease that affects almost every organ and organ system in the human body. The immune system attacks the body's own tissues in this condition, causing significant inflammation and tissue damage in the organs implicated. Swollen joints, unexplained fever, chest discomfort, hair loss, mouth ulcers, enlarged lymph nodes, severe tiredness, and red rashes on the face are some of the most prevalent symptoms of SLE.

SLE is a highly undertreated condition with few viable therapy choices available worldwide. GSK's Benlysta (authorised by the US FDA in 2011 and China's NMPA in 2019), Astra Zeneca's Saphnelo (approved by the FDA in August 2021), and RemeGen's telitacicept (approved by China's NMPA in 2021) are the only biologic therapies approved in this indication globally. However, given enormous unmet medical need, the market would expand in the coming years. The global systemic lupus erythematosus market is expected to reach US$2.18 billion in 2023, progressing at a CAGR of 7.52% over the forecasted period.

Segment Covered:

By Product Type: The market report has segmented the global systemic lupus erythematosus market into six segments in terms of product type: Biologics, NSAIDs, Antimalarial Drugs, Corticosteroids, Immunosuppressants and Others. The biologics segment lead the market with largest share. Demand for drugs with better efficacy and safety profile have increased among people. Biologics are safer than many other products, and can be used to treat women during pregnancy. The market is expected to grow at the highest CAGR, due to technological advancements in biologics.
By Route of Administration: The report splits the global market into three segments on the basis of route of administration: Oral, Intravenous and Subcutaneous. The oral segment dominated the market by occupying maximum share of the market. Oral route of administration is convenient, safe and cost effective. Therefore, on most of the times, people prefer to use oral route of administration in SLE treatment. Subcutaneous segment is projected to grow at the highest CAGR over the forecast period.
By End User: According to report, the market has been segmented into three segments, based on end user: Hospitals, Drug Lab and Others. The hospital segment dominated the market with majority share. The hospital segment is expected to grow rapidly due to initiatives taken by several government around the world. Some hospitals are also providing free treatment to the SLE patients. Demand for drugs is increasing with increasing number od SLE patients and therefore drug lab segment would also grow in the coming years.

Geographic Coverage:

According to this report, the global systemic lupus erythematosus market is divided into five regions: North America, Europe, Asia Pacific, Latin America and Middle East & Africa. The countries covered in North America region include the US, Canada, and Mexico, while Europe includes UK, Germany, France, Spain, Italy and Rest of Europe.

North America dominated the market, by occupying largest share of the global market. Factors such as increasing prevalence of lupus and presence of prominent players have supported the growth of the systemic lupus erythematosus market in the region. On the other hand, the Asia Pacific network detection and response market is the emerging region in the global market, due to increasing adoption of cloud-based solutions by both large enterprises and SMEs in the region.

Top Impacting Factors:

Growth Drivers

Increasing Healthcare Expenditure
Increasing Female Population
Favorable Government Initiatives
Rising Prevalence of SLE Disease

Challenges

Stringent Regulatory Environment
High Cost of Drug Development

Trends

Rising Clinical Trials
Adoption of Stem Cell Therapy
Rising Awareness Among People
Driver: Increasing Healthcare Expenditure

As the economy advances, there comes a need for a proper healthcare infrastructure and subsequent technological advancement in the health sector. Investments in health care and research and development have made the development of medicines, treatments, and vaccinations easier and more effective. As a result of rising healthcare spending, the SLE market has become more advanced and accessible in recent years, and enhanced technology has paved the way for new drugs, therapies and antibodies, thus driving the growth of the market.

Challenge: Stringent Regulatory Environment

Traditionally, all vaccinations, medical gadgets, and helpful medications developed to treat certain diseases have undergone extensive testing in clinical trials to ensure their safety and feasibility in treating the disease. These trials are very time consuming and rules and regulations associated with it are very stringent. Due to this reason, research organizations or pharmaceutical companies have to experience slow progress towards regulatory approvals. Because of the uncertainty in the trials only a few pharmaceutical companies are able to enter the market since they can bear the loss. Therefore, it is difficult for small and medium drug manufacturers to enter into the market. Apart from that recruitment, enrollment and retention of patients for trial is an another challenge to the drug manufacturer. Since, without a standard number of participants any kind of drug trial can not be approved.

Trend: Rising Awareness Among People

Autoimmune disease like systemic lupus erythematosus (SLE) is rare therefore a few people know about its severity and treatments. But, now people are more aware about this disease than before due to several awareness campaigns. Every year, events are held to educate the public about lupus and how it affects individuals. Furthermore, fundraising aids research initiatives as well as families whose lives have been affected by the disease. These events raise awareness of the physical, emotional, and financial consequences of lupus. People fighting the disease will receive better support, resources, and advocacy as their awareness grows. Therefore, rising awareness among the people through this type of events by various organizations would drive the market growth in the coming years.

The COVID-19 Analysis:

In the early phases of the pandemic, the world was put under lockdown to stop the virus from spreading, suspending the majority of commercial operations. The lockdown had a huge influence on industries that are considered the backbone of the world economy, such as manufacturing, aviation, tourism, and so on, causing the global economy to enter a recession. The healthcare businesses encountered a number of challenges during the early stages of the pandemic. The availability of doctors, health workers as well as the supply of medical devices, diagnostics, and treatments, were all affected. Regular identification and treatment of other diseases were missed in the first half of 2020, because entire healthcare sector was focused on preventing, detecting and treating COVID-19.

On the contrary, as the lockdowns were gradually released near the second half of 2020, there was an increase in the number of patients seeking treatment for autoimmune diseases. Healthcare sector restored to normal as rate of transmission was reduced. Treatment for autoimmune diseases began at a better pace. As a result, COVID-19 had a short-term detrimental impact on the systemic lupus erythematosus market.

Analysis of Key Players:

The global market for systemic lupus erythematosus is fragmented. Most of the approved therapies for SLE are small molecule immunosuppressive agents such as azathioprine (first approved by the FDA in 1968), mycophenolate mofetil (first approved by the FDA in 1995) and methotrexate (first approved by the FDA in 1953), all of which are now off-patent and being marketed by multiple pharmaceutical companies in generic forms.

Beyond these small molecule drugs, there are currently two biologic drugs approved for the treatment of SLE globally: GSK's belimumab (approved by the FDA in 2011 and NMPA in 2019) and RemeGen's Telitacicept (approved by the NMPA in 2021 and not approved yet in the US). Beyond these two approved products, there are two innovative biologics for the treatment of SLE in phase III development in the US (along with eighteen other molecules in Phase I/II) and no Phase III pipeline assets in China (but five assets in Phase I/II). The key players of the global systemic lupus erythematosus market are:

Novartis AG
Hoffmann-LA-Roche Ltd.
Pfizer, Inc.
AstraZeneca Plc
GlaxoSmithKline Plc
Merck & Co., Inc.
Abbvie, Inc
Biotest AG
Sanofi
Boston Pharmaceuticals
UCB SA
RemeGen Co., Ltd.
Amgen Inc.
Xencor, Inc.

Hoffmann-LA-Roche Ltd., Pfizer, Inc., Abbvie, Inc. are some of the major drug manufacturer and have a dominance around the world. However, company like AstraZeneca Plc has a strong presence in the vaccine development and manufacturing as well. GlaxoSmithKline plc. is also a significant participant in the market with segments like pharmaceuticals, consumer healthcare, vaccine, etc.

1. Executive Summary

2. Introduction

2.1 Systemic Lupus Erythematosus (SLE): An Overview
2.2 Systemic Lupus Erythematosus (SLE) Segmentation: An Overview

3. Global Market Analysis

3.1 Global Systemic Lupus Erythematosus Market: An Analysis
- 3.1.1 Global Systemic Lupus Erythematosus Market by Value
- 3.1.2 Global Systemic Lupus Erythematosus Market by Number of Patients
- 3.1.3 Global Systemic Lupus Erythematosus Market by Product Type (Biologics, NSAIDs, Antimalarial Drugs, Corticosteroids, Immunosuppressants and Others)
- 3.1.4 Global Systemic Lupus Erythematosus Market by Route of Administration (Oral, Intravenous and Subcutaneous)
- 3.1.5 Global Systemic Lupus Erythematosus Market by End User (Hospitals, Drug Lab and Others)
- 3.1.6 Global Systemic Lupus Erythematosus Market by Region (North America, Europe, Asia Pacific, Latin America and Middle East & Africa)
3.2 Global Systemic Lupus Erythematosus Market: Product Analysis
- 3.2.1 Global Biologics Systemic Lupus Erythematosus Market by Value
- 3.2.2 Global NSAIDs Systemic Lupus Erythematosus Market by Value
- 3.2.3 Global Antimalarial Drugs Systemic Lupus Erythematosus Market by Value
- 3.2.4 Global Corticosteroids Systemic Lupus Erythematosus Market by Value
- 3.2.5 Global Immunosuppressant Systemic Lupus Erythematosus Market by Value
- 3.2.6 Global Others Systemic Lupus Erythematosus Market by Value
3.3 Global Systemic Lupus Erythematosus Market: Route of Administration Analysis
- 3.3.1 Global Oral Systemic Lupus Erythematosus Market by Value
- 3.3.2 Global Intravenous Systemic Lupus Erythematosus Market by Value
- 3.3.3 Global Subcutaneous Systemic Lupus Erythematosus Market by Value
3.4 Global Systemic Lupus Erythematosus Market: End User Analysis
- 3.4.1 Global Hospitals Systemic Lupus Erythematosus Market by Value
- 3.4.2 Global Drug Lab Systemic Lupus Erythematosus Market by Value
- 3.4.3 Global Others Systemic Lupus Erythematosus Market by Value

4. Regional Market Analysis

4.1 North America Systemic Lupus Erythematosus Market: An Analysis
- 4.1.1 North America Systemic Lupus Erythematosus Market by Value
- 4.1.2 North America Systemic Lupus Erythematosus Market by Region (The US, Canada and Mexico)
- 4.1.3 The US Systemic Lupus Erythematosus Market by Value
- 4.1.4 The US Systemic Lupus Erythematosus Market by Number of Patients
- 4.1.5 Canada Systemic Lupus Erythematosus Market by Value
- 4.1.6 Mexico Systemic Lupus Erythematosus Market by Value
4.2 Europe Systemic Lupus Erythematosus Market: An Analysis
- 4.2.1 Europe Systemic Lupus Erythematosus Market by Value
- 4.2.2 Europe Systemic Lupus Erythematosus Market by Region (UK, Germany, France, Spain, Italy and Rest of Europe)
- 4.2.3 UK Systemic Lupus Erythematosus Market by Value
- 4.2.4 Germany Systemic Lupus Erythematosus Market by Value
- 4.2.5 France Systemic Lupus Erythematosus Market by Value
- 4.2.6 Spain Systemic Lupus Erythematosus Market by Value
- 4.2.7 Italy Systemic Lupus Erythematosus Market by Value
- 4.2.8 Rest of Europe Systemic Lupus Erythematosus Market by Value
4.3 Asia pacific Systemic Lupus Erythematosus Market: An Analysis
- 4.3.1 Asia pacific Systemic Lupus Erythematosus Market by Value
4.4 Middle East & Africa Systemic Lupus Erythematosus Market: An Analysis
- 4.4.1 Middle East & Africa Systemic Lupus Erythematosus Market by Value
4.5 Latin America Systemic Lupus Erythematosus Market: An Analysis
- 4.5.1 Latin America Systemic Lupus Erythematosus Market by Value

5. Impact of COVID-19

5.1 Impact of COVID-19
- 5.1.1 Impact of COVID-19 on Healthcare
- 5.1.2 Impact of COVID-19 on Systemic Lupus Erythematosus Market

6. Market Dynamics

6.1 Growth Drivers
- 6.1.1 Increasing Healthcare Expenditure
- 6.1.2 Increasing Female Population
- 6.1.3 Rapid Urbanization
- 6.1.4 Favorable Government Initiatives
- 6.1.5 Rising Prevalence of SLE Disease
6.2 Challenges
- 6.2.1 Stringent Regulatory Environment
- 6.2.2 High Cost of Drug Development
6.3 Trends
- 6.3.1 Rising Clinical Trials
- 6.3.2 Adoption of Stem Cell Therapy
- 6.3.3 Rising Awareness Among People

7. Competitive Landscape

7.1 The US and China Systemic Lupus Erythematosus Market Players by Marketed Biologics for SLE Treatment
7.2 The US and China Systemic Lupus Erythematosus Market players by Pipeline Biologics for SLE Treatment

8. Company Profiles

8.1 Hoffmann-LA- Roche Ltd.
- 8.1.1 Business Overview
- 8.1.2 Operating Segments
- 8.1.3 Business Strategies
8.2 Pfizer, Inc.
- 8.2.1 Business Overview
- 8.2.2 Operating Segments
- 8.2.3 Business Strategies
8.3 AbbVie, Inc.
- 8.3.1 Business Overview
- 8.3.2 Operating Segments
- 8.3.3 Business Strategies
8.4 Novartis AG
- 8.4.1 Business Overview
- 8.4.2 Operating Segments
- 8.4.3 Business Strategies
8.5 AstraZeneca Plc
- 8.5.1 Business Overview
- 8.5.2 Operating Segments
- 8.5.3 Business Strategies
8.6 GlaxoSmithKline plc
- 8.6.1 Business Overview
- 8.6.2 Operating Segments
- 8.6.3 Business Strategies
8.7 Merck & Co., Inc.
- 8.7.1 Business Overview
- 8.7.2 Operating Segments
- 8.7.3 Business Strategies
8.8 UCB SA
- 8.8.1 Business Overview
- 8.8.2 Operating Regions
- 8.8.3 Business Strategies
8.9 RemeGen Co., Ltd.
- 8.9.1 Business Overview
- 8.9.2 Operating Regions
- 8.9.3 Business Strategies
8.10 Amgen Inc.
- 8.10.1 Business Overview
- 8.10.2 Operating Region
- 8.10.3 Business Strategies
8.11 Biotest AG
- 8.11.1 Business Overview
- 8.11.2 Operating Segments
- 8.11.3 Business Strategies
8.12 Xencor, Inc.
- 8.12.1 Business Overview
- 8.12.2 Revenue By Operations
- 8.12.3 Business Strategies
8.13 Sanofi
- 8.13.1 Business Overview
- 8.13.2 Operating Segments
- 8.13.3 Business Strategies
8.14 Boston Pharmaceuticals
- 8.14.1 Business Overview
- 8.14.2 Business Strategies
Table of Figures
Figure 1: Systemic Lupus Erythematosus (SLE) Segmentation
Figure 2: Global Systemic Lupus Erythematosus Market by Value; 2017-2021 (US$ Billion)
Figure 3: Global Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Billion)
Figure 4: Global Systemic Lupus Erythematosus Market by Number of Patients; 2020-2021 (Million)
Figure 5: Global Systemic Lupus Erythematosus Market by Number of Patients; 2022-2026 (Million)
Figure 6: Global Systemic Lupus Erythematosus Market by Product Type; 2021 (Percentage, %)
Figure 7: Global Systemic Lupus Erythematosus Market by Route of Administration; 2021 (Percentage, %)
Figure 8: Global Systemic Lupus Erythematosus Market by End User; 2021 (Percentage, %)
Figure 9: Global Systemic Lupus Erythematosus Market by Region; 2021 (Percentage, %)
Figure 10: Global Biologics Systemic Lupus Erythematosus Market by Value; 2017-2021 (US$ Million)
Figure 11: Global Biologics Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
Figure 12: Global NSAIDs Systemic Lupus Erythematosus Market by Value; 2017-2021 (US$ Million)
Figure 13: Global NSAIDs Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
Figure 14: Global Antimalarial Drugs Systemic Lupus Erythematosus Market by Value; 2017-2021 (US$ Million)
Figure 15: Global Antimalarial Drugs Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
Figure 16: Global Corticosteroids Systemic Lupus Erythematosus Market by Value; 2017-2021 (US$ Million)
Figure 17: Global Corticosteroids Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
Figure 18: Global Immunosuppressant Systemic Lupus Erythematosus Market by Value; 2017-2021 (US$ Million)
Figure 19: Global Immunosuppressant Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
Figure 20: Global Others Systemic Lupus Erythematosus Market by Value; 2017-2021 (US$ Million)
Figure 21: Global Others Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
Figure 22: Global Oral Systemic Lupus Erythematosus Market by Value; 2017-2021 (US$ Million)
Figure 23: Global Oral Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Billion)
Figure 24: Global Intravenous Systemic Lupus Erythematosus Market by Value; 2017-2021 (US$ Million)
Figure 25: Global Intravenous Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
Figure 26: Global Subcutaneous Systemic Lupus Erythematosus Market by Value; 2017-2021 (US$ Million)
Figure 27: Global Subcutaneous Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
Figure 28: Global Hospitals Systemic Lupus Erythematosus Market by Value; 2017-2021 (US$ Million)
Figure 29: Global Hospitals Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
Figure 30: Global Drug Lab Systemic Lupus Erythematosus Market by Value; 2017-2021 (US$ Million)
Figure 31: Global Drug Lab Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
Figure 32: Global Others Systemic Lupus Erythematosus Market by Value; 2017-2021 (US$ Million)
Figure 33: Global Others Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
Figure 34: North America Systemic Lupus Erythematosus Market by Value; 2017-2021 (US$ Million)
Figure 35: North America Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
Figure 36: North America Systemic Lupus Erythematosus Market by Region; 2021 (Percentage, %)
Figure 37: The US Systemic Lupus Erythematosus Market by Value; 2020-2021 (US$ Million)
Figure 38: The US Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
Figure 39: The US Systemic Lupus Erythematosus Market by Number of Patients; 2020-2021 (Thousand)
Figure 40: The US Systemic Lupus Erythematosus Market by Number of Patients; 2022-2026 (Thousand)
Figure 41: Canada Systemic Lupus Erythematosus Market by Value; 2020-2021 (US$ Million)
Figure 42: Canada Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
Figure 43: Mexico Systemic Lupus Erythematosus Market by Value; 2020-2021 (US$ Million)
Figure 44: Mexico Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
Figure 45: Europe Systemic Lupus Erythematosus Market by Value; 2017-2021 (US$ Million)
Figure 46: Europe Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
Figure 47: Europe Systemic Systemic Lupus Erythematosus Market by Region; 2021 (Percentage, %)
Figure 48: UK Systemic Lupus Erythematosus Market by Value; 2020-2021 (US$ Million)
Figure 49: UK Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
Figure 50: Germany Systemic Lupus Erythematosus Market by Value; 2020-2021 (US$ Million)
Figure 51: Germany Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
Figure 52: France Systemic Lupus Erythematosus Market by Value; 2020-2021 (US$ Million)
Figure 53: France Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
Figure 54: Spain Systemic Lupus Erythematosus Market by Value; 2020-2021 (US$ Million)
Figure 55: Spain Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
Figure 56: Italy Systemic Lupus Erythematosus Market by Value; 2020-2021 (US$ Million)
Figure 57: Italy Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
Figure 58: Rest of Europe Systemic Lupus Erythematosus Market by Value; 2020-2021 (US$ Million)
Figure 59: Rest of Europe Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
Figure 60: Asia pacific Systemic Lupus Erythematosus Market by Value; 2017-2021 (US$ Million)
Figure 61: Asia pacific Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
Figure 62: Middle East & Africa Systemic Lupus Erythematosus Market by Value; 2017-2021 (US$ Million)
Figure 63: Middle East & Africa Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
Figure 64: Latin America Systemic Lupus Erythematosus Market by Value; 2017-2021 (US$ Million)
Figure 65: Latin America Systemic Lupus Erythematosus Market by Value; 2022-2026 (US$ Million)
Figure 66: The US Health Consumption Expenditure as a Percentage of GDP; 2015-2020 (Percentage, %)
Figure 67: Global Female Population of Age Group 15-44; 2005-2020 (Billion)
Figure 68: Global Urban Population as a Share of Total Population; 2016-2021 (Percentage, %)
Figure 69: Hoffmann-La-Roche Ltd. Sales by Business Divisions; 2021 (Percentage, %)
Figure 70: Pfizer Inc. Revenues by Operating Segments; 2021 (Percentage, %)
Figure 71: Abbvie, Inc. Net Revenues by Products; 2021 (Percentage, %)
Figure 72: Novartis AG Net Sales by Segment; 2021 (Percentage, %)
Figure 73: AstraZeneca Plc Total Revenue by Product; 2021 (Percentage, %)
Figure 74: GlaxoSmithKline plc Turnover by Segments; 2021 (Percentage, %)
Figure 75: Merck & Co., Inc. Total Sales by Segments; 2021 (Percentage, %)
Figure 76: UCB SA Net Sales by Region; 2021 (Percentage, %)
Figure 77: RemeGen Co., Ltd. Revenue by Region; 2021 (Percentage, %)
Figure 78: Amgen Inc. Revenue by Region; 2021 (Percentage, %)
Figure 79: Biotest AG Sales by Segment; 2021 (Percentage, %)
Figure 80: Xencor, Inc. Revenue by Operations; 2021 (Percentage, %)
Figure 81: Sanofi Net Sales by segments; 2021 (Percentage, %)
Table 1: The US and China Systemic Lupus Erythematosus Market Players by Marketed Biologics for SLE Treatment
Table 2: The US and China Systemic Lupus Erythematosus Market Players by Pipeline Biologics for SLE Treatment